POSB26 Real-World Effectiveness of Fremanezumab Treatment for Reducing Monthly Migraine and Headache Days in US Patients Having Different Numbers of PRIOR Migraine Preventive Treatment Failures
Cohen, J, Thompson, S, Sun, R, Driessen, M, Seminerio, M, Carr, K, Mu, F
Published in Value in health (01.01.2022)
Published in Value in health (01.01.2022)
Get full text
Journal Article
Reduction in migraine days with aura with fremanezumab in patients with documented inadequate response to 2-4 classes of migraine preventive medications in the focus study
Ashina, M., Cohen, J.M., Yang, R., Ramirez-Campos, V., Seminerio, M., Lampl, C.
Published in Journal of the neurological sciences (15.10.2019)
Published in Journal of the neurological sciences (15.10.2019)
Get full text
Journal Article
PND61 Adverse Event Profiles of Therapies That Target the Calcitonin GENE-Related Peptide (CGRP) Pathway, during the First SIX Months after Launch: A Real-World DATA Analysis Using the FDA Adverse Events Reporting System (FAERS)
Silberstein, S.D., Reshef, S., Cohen, J.M., Gandhi, S., Seminerio, M., Ramirez-Campos, V., Kessler, Y., Thompson, S.F., Blumenfeld, A.
Published in Value in health (01.12.2020)
Published in Value in health (01.12.2020)
Get full text
Journal Article
POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting
Driessen, M, Patterson-Lomba, O, Mu, F, Thompson, S, Seminerio, M, Carr, K, Sun, R, Totev, T, Yim, E, Ayyagari, R, Cohen, J
Published in Value in health (01.01.2022)
Published in Value in health (01.01.2022)
Get full text
Journal Article
EE57 Real-World Reductions in Migraine-Related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab: A 12-Month Retrospective US Claims Analysis
Driessen, MT, Krasenbaum, LJ, Ramirez-Campos, V, DiEgidio, R, Tian, M, Seminerio, MJ
Published in Value in health (01.07.2022)
Published in Value in health (01.07.2022)
Get full text
Journal Article
EE226 A US Claims Database Analysis of the Impact of Fremanezumab on Migraine-Related Health Care Utilization and Costs in Patients with Common Comorbidities, Acute Medication Overuse, or Difficult-to-Treat Migraine Following Prior Erenumab Use
Buse, DC, Driessen, MT, Krasenbaum, LJ, Seminerio, MJ, Carr, K, Ortega, M, Packnett, E
Published in Value in health (01.07.2022)
Published in Value in health (01.07.2022)
Get full text
Journal Article
EE19 A Retrospective US Claims Database Analysis of the Impact of Fremanezumab on Migraine-Related Health Care Utilization and Costs in Patients with Potential Acute Medication Overuse
Buse, DC, Driessen, MT, Krasenbaum, LJ, Seminerio, MJ, Carr, K, Ortega, M, Packnett, E
Published in Value in health (01.07.2022)
Published in Value in health (01.07.2022)
Get full text
Journal Article
EE433 A US Claims Database Analysis of the Impact of Fremanezumab on Migraine-Related Health Care Utilization and Costs in Patients with Common Comorbidities, Acute Medication Overuse, or Difficult-to-Treat Migraine
Buse, DC, Driessen, MT, Krasenbaum, LJ, Seminerio, MJ, Carr, K, Ortega, M, Packnett, E
Published in Value in health (01.07.2022)
Published in Value in health (01.07.2022)
Get full text
Journal Article
26-Year-Old Man With Recurrent Urinary Tract Infections
Seminerio, Jennifer L., MD, Aggarwal, Gaurav, MD, Sweetser, Seth, MD
Published in Mayo Clinic proceedings (01.06.2011)
Published in Mayo Clinic proceedings (01.06.2011)
Get full text
Journal Article